Literature DB >> 10776692

Plasma-soluble Fas (APO-1, CD95) and soluble Fas ligand in immune thrombocytopenic purpura.

C Yoshimura1, S Nomura, M Nagahama, Y Ozaki, H Kagawa, S Fukuhara.   

Abstract

We investigated the levels of various cytokines and soluble factors in ITP patients, in order to determine the influence of these factors on the pathogenesis of ITP. We found increases in IL-2, IL-6, IFN-gamma, and M-CSF levels in ITP patients compared with those in healthy individuals. On lymphocyte phenotype analysis, we found no clear difference in total T cell population (CD2+ CD19- cells) or cytotoxic T cell frequency (CD8+ CD11b- cells) between these two groups. The frequency of helper/inducer T cells (CD4+ CD8- cells) was decreased in ITP patients. There was a significant increase in activated T cells (CD3+ HLA-DR+ cells) in ITP patients. Furthermore, frequencies of NK cells of potent activity (CD16+ CD56+ cells) were significantly elevated in ITP patients. Seventeen of the 54 ITP patients (31.5%) had elevated levels of sFas, and 11 of the 54 patients (20.4%) of sFasL. In addition, a significant increase of sFasL was observed in sFas-positive ITP patients, and in these patients the sFasL level was correlated with that of sFas (r = 0.687, p < 0.01). We found significant increases in IL-2 and sIL-2R levels in sFas-positive ITP patients. For other factors examined, however, there were no differences in level between sFas-positive and -negative ITP patients. Percentages of activated T cells (CD3+ and HLA-DR+ cells) and NK cells (CD16+ and CD56+ cells) were significantly higher in sFas-positive ITP patients than in sFas-negative ITP patients. These findings suggests that the pathogenesis of ITP includes alteration of the Fas/FasL pathway.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10776692     DOI: 10.1034/j.1600-0609.2000.9o096.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  4 in total

1.  Characterization of Th1- and Th2-associated chemokine receptor expression in spleens of patients with immune thrombocytopenia.

Authors:  Shu-Fen Zhou; Ji Ma; Hui-Ting Qu; Zong-Tang Liu; Wei-Dong He; Juan-Dong Wang; Ai-Xia Dou; Ni Zhang; Jun-Li Liu; Cheng-Shan Guo; Yan Shi; Ming Hou; Jun Peng
Journal:  J Clin Immunol       Date:  2013-03-14       Impact factor: 8.317

2.  Favorable response of chronic refractory immune thrombocytopenic purpura to mesenchymal stem cells.

Authors:  Baijun Fang; Ling Mai; Ning Li; Yongping Song
Journal:  Stem Cells Dev       Date:  2011-08-12       Impact factor: 3.272

3.  Correction of Th1-dominant cytokine profiles by high-dose dexamethasone in patients with chronic idiopathic thrombocytopenic purpura.

Authors:  Chengshan Guo; Xiaoxia Chu; Yan Shi; Weidong He; Lizhen Li; Lin Wang; Yingxue Wang; Jun Peng; Ming Hou
Journal:  J Clin Immunol       Date:  2007-07-06       Impact factor: 8.317

4.  Elevated Concentrations of Soluble Fas and FasL in Multiple Sclerosis Patients with Antinuclear Antibodies.

Authors:  Josip Sremec; Sanja Tomasović; Nada Tomić Sremec; Alan Šućur; Jelena Košćak Lukač; Koraljka Bačić Baronica; Danka Grčević; Nataša Kovačić
Journal:  J Clin Med       Date:  2020-11-26       Impact factor: 4.241

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.